What is Fluid Biotech?
Founded in 2012, Fluid Biotech specializes in the engineering of advanced medical devices, most notably its flagship implantable dissolving stent. This technology is designed to facilitate the diversion of blood flow while simultaneously promoting the natural healing of blood vessels. By focusing on bio-resorbable materials, the company addresses significant limitations associated with traditional permanent implants, offering a more physiological solution for vascular repair. Headquartered in Calgary, Alberta, the firm operates at the intersection of material science and clinical neurology, aiming to redefine standards of care for patients requiring vascular intervention.
How much funding has Fluid Biotech raised?
Fluid Biotech has raised a total of $4.7M across 1 funding round:
Angel/Seed
$4.7M
Angel/Seed (2021): $4.7M with participation from METIS Innovative and ShangBay Capital
Key Investors in Fluid Biotech
METIS Innovative
A physician-founded investment firm specializing in neurotechnology and medical breakthroughs, dedicated to improving outcomes for patients with neurologic conditions.
ShangBay Capital
A Palo Alto-based venture capital firm focused on early-stage investments within the biotechnology and medical device sectors.
What's next for Fluid Biotech?
With the successful closure of this funding round, Fluid Biotech is expected to prioritize the advancement of its clinical trials and the refinement of its manufacturing processes. The strategic deployment of these funds will likely focus on expanding the company's research and development capabilities to support the commercialization of its bio-resorbable stent technology. Furthermore, the firm is well-positioned to strengthen its intellectual property portfolio and pursue regulatory milestones that are essential for market entry. As the company scales, it will likely seek to deepen its collaborative efforts with clinical partners to validate the long-term efficacy of its devices in diverse patient populations, ultimately aiming to establish a new benchmark in neurovascular and cardiovascular treatment.
See full Fluid Biotech company page
